Literature DB >> 23512985

Triplication of DYRK1A causes retinal structural and functional alterations in Down syndrome.

Ariadna Laguna1, María-José Barallobre, Miguel-Ángel Marchena, Catarina Mateus, Erika Ramírez, Carmen Martínez-Cue, Jean M Delabar, Miguel Castelo-Branco, Pedro de la Villa, Maria L Arbonés.   

Abstract

Down syndrome (DS) results from the triplication of approximately 300 human chromosome 21 (Hsa21) genes and affects almost all body organs. Children with DS have defects in visual processing that may have a negative impact on their daily life and cognitive development. However, there is little known about the genes and pathogenesis underlying these defects. Here, we show morphometric in vivo data indicating that the neural retina is thicker in DS individuals than in the normal population. A similar thickening specifically affecting the inner part of the retina was also observed in a trisomic model of DS, the Ts65Dn mouse. Increased retinal size and cellularity in this model correlated with abnormal retinal function and resulted from an impaired caspase-9-mediated apoptosis during development. Moreover, we show that mice bearing only one additional copy of Dyrk1a have the same retinal phenotype as Ts65Dn mice and normalization of Dyrk1a gene copy number in Ts65Dn mice completely rescues both, morphological and functional phenotypes. Thus, triplication of Dyrk1a is necessary and sufficient to cause the retinal phenotype described in the trisomic model. Our data demonstrate for the first time the implication of DYRK1A overexpression in a developmental alteration of the central nervous system associated with DS, thereby providing insights into the aetiology of neurosensorial dysfunction in a complex disease.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23512985     DOI: 10.1093/hmg/ddt125

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  25 in total

1.  DSCAM promotes refinement in the mouse retina through cell death and restriction of exploring dendrites.

Authors:  Shuai Li; Joshua M Sukeena; Aaron B Simmons; Ethan J Hansen; Renee E Nuhn; Ivy S Samuels; Peter G Fuerst
Journal:  J Neurosci       Date:  2015-04-08       Impact factor: 6.167

2.  DYRK1A haploinsufficiency causes a new recognizable syndrome with microcephaly, intellectual disability, speech impairment, and distinct facies.

Authors:  Jianling Ji; Hane Lee; Bob Argiropoulos; Naghmeh Dorrani; John Mann; Julian A Martinez-Agosto; Natalia Gomez-Ospina; Natalie Gallant; Jonathan A Bernstein; Louanne Hudgins; Leah Slattery; Bertrand Isidor; Cédric Le Caignec; Albert David; Ewa Obersztyn; Barbara Wiśniowiecka-Kowalnik; Michelle Fox; Joshua L Deignan; Eric Vilain; Emily Hendricks; Margaret Horton Harr; Sarah E Noon; Jessi R Jackson; Alisha Wilkens; Ghayda Mirzaa; Noriko Salamon; Jeff Abramson; Elaine H Zackai; Ian Krantz; A Micheil Innes; Stanley F Nelson; Wayne W Grody; Fabiola Quintero-Rivera
Journal:  Eur J Hum Genet       Date:  2015-05-06       Impact factor: 4.246

3.  Macular structural characteristics in children with Down syndrome.

Authors:  Scott O'Brien; Jingyun Wang; Heather A Smith; Dana L Donaldson; Kathryn M Haider; Gavin J Roberts; Derek T Sprunger; Daniel E Neely; David A Plager
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-07-02       Impact factor: 3.117

4.  Segmentation of the foveal and parafoveal retinal architecture using handheld spectral-domain optical coherence tomography in children with Down syndrome.

Authors:  Catherine M Hill; Helena Lee; Rory Nicholson; Daniel Osborne; Lisa Fairhead; Leonora Beed
Journal:  Eye (Lond)       Date:  2022-01-10       Impact factor: 4.456

5.  Dyrk1A induces pancreatic β cell mass expansion and improves glucose tolerance.

Authors:  Latif Rachdi; Dulanjalee Kariyawasam; Virginie Aïello; Yann Herault; Nathalie Janel; Jean-Maurice Delabar; Michel Polak; Raphaël Scharfmann
Journal:  Cell Cycle       Date:  2014-05-28       Impact factor: 4.534

6.  Disruptive de novo mutations of DYRK1A lead to a syndromic form of autism and ID.

Authors:  B W M van Bon; B P Coe; R Bernier; C Green; J Gerdts; K Witherspoon; T Kleefstra; M H Willemsen; R Kumar; P Bosco; M Fichera; D Li; D Amaral; F Cristofoli; H Peeters; E Haan; C Romano; H C Mefford; I Scheffer; J Gecz; B B A de Vries; E E Eichler
Journal:  Mol Psychiatry       Date:  2015-02-24       Impact factor: 15.992

7.  Ocular Phenotype Associated with DYRK1A Variants.

Authors:  Cécile Méjécase; Christopher M Way; Nicholas Owen; Mariya Moosajee
Journal:  Genes (Basel)       Date:  2021-02-05       Impact factor: 4.096

8.  DYRK1A controls the transition from proliferation to quiescence during lymphoid development by destabilizing Cyclin D3.

Authors:  Benjamin J Thompson; Rahul Bhansali; Lauren Diebold; Daniel E Cook; Lindsay Stolzenburg; Anne-Sophie Casagrande; Thierry Besson; Bertrand Leblond; Laurent Désiré; Sébastien Malinge; John D Crispino
Journal:  J Exp Med       Date:  2015-05-25       Impact factor: 14.307

9.  Identification of a novel actin-dependent signal transducing module allows for the targeted degradation of GLI1.

Authors:  Philipp Schneider; Juan Miguel Bayo-Fina; Rajeev Singh; Pavan Kumar Dhanyamraju; Philipp Holz; Aninja Baier; Volker Fendrich; Annette Ramaswamy; Stefan Baumeister; Elisabeth D Martinez; Matthias Lauth
Journal:  Nat Commun       Date:  2015-08-27       Impact factor: 14.919

10.  PSEA: Kinase-specific prediction and analysis of human phosphorylation substrates.

Authors:  Sheng-Bao Suo; Jian-Ding Qiu; Shao-Ping Shi; Xiang Chen; Ru-Ping Liang
Journal:  Sci Rep       Date:  2014-03-31       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.